474 — Aceso Life Science Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.17bn
- HK$4.06bn
- HK$312.00m
Annual cashflow statement for Aceso Life Science, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -481 | -267 | -323 | -555 | -213 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 443 | 252 | 402 | 592 | 251 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -103 | -398 | 37 | 211 | 132 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -83.9 | -356 | 179 | 316 | 222 |
| Capital Expenditures | -70.7 | -36.2 | -15 | -57 | -47 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,177 | 1,030 | 15 | -384 | -73 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,247 | 994 | 0 | -441 | -120 |
| Financing Cash Flow Items | -0.689 | -214 | -113 | -163 | 43 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 824 | -522 | -375 | 126 | -98 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -514 | 115 | -184 | -3 | -8 |